Sjögren syndrome and fibromyalgia after radioiodine therapy in cancer thyroid patients  by Gheita, Tamer A et al.
The Egyptian Rheumatologist (2011) 33, 107–112Egyptian Society for Joint Diseases and Arthritis
The Egyptian Rheumatologist
www.rheumatology.eg.net
www.sciencedirect.comORIGINAL ARTICLESjo¨gren syndrome and ﬁbromyalgia after radioiodine
therapy in cancer thyroid patientsTamer A Gheita a, Samar M Fawzy a,*, Ahmed A Kandeel b, Hossam M. Khalil ca Rheumatology Department, Faculty of Medicine, Cairo University, Egypt
b Nuclear Medicine Department, Faculty of Medicine, Cairo University, Egypt
c Ophthalmology Department, Faculty of Medicine, Cairo University, EgyptReceived 15 February 2011; accepted 5 March 2011
Available online 4 May 2011*
Eg
E-
11
Pr
Pe
an
doKEYWORDS
Sjo¨gren syndrome;
Fibromyalgia syndrome;
Radioiodine therapyCorresponding author. Add
ypt. Tel.: +2 0101805126; f
mail address: samarfawzy1@
10-1164  2011 Egyptian So
oduction and hosting by Els
er review under responsibility
d Arthritis.
i:10.1016/j.ejr.2011.03.007
Production and h
Open access under CC BY-NC-ress: 17
ax: +2 0
yahoo.co
ciety for
evier B.V
of Egyp
osting by E
ND licenseAbstract Introduction: Salivary and lacrimal gland dysfunction is relatively frequent after radio-
iodine therapy. An association of Sjo¨gren’s syndrome (SS) and other autoimmune rheumatic dis-
eases as ﬁbromyalgia syndrome (FMS) has been reported. Thyroid autoimmunity in FMS
patients is higher than normal subjects.
Aim of the work: To detect the occurrence of Sjo¨gren syndrome (SS) and any rheumatologic
association in cancer thyroid patients after radioactive iodine therapy (I-131) and evaluate the sal-
ivary and lacrimal glands function.
Patients and Methods: Thirty-one patients with post-surgical differentiated thyroid carcinomas
with a mean age 40.13±9.82 years, were referred for I-131 therapy (mean dose
212.9 ± 101.63 mCi) and continued the follow-up study. All patients had no symptoms or signs
of SS. Thorough rheumatological examination was performed for any musculoskeletal manifesta-
tion or associated ﬁbromyalgia syndrome (FMS). Before and 8–12 months after I-131 therapy, sal-
ivary glands function was estimated by sequential scintigraphy, while lacrimal gland function was
assessed by Schirmer’s test. Antinuclear antibody (ANA), anti-Ro (SS-A), anti-La (SS-B) and rheu-
matoid factor (RF) were performed.Sheikh Ali Youssif, Cairo,
2 25085372.
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108 T.A Gheita et al.Results: All patients had a normal salivary glands scintigraphy and Schirmer’s test before I-131
therapy. On follow up, primary SS occurred in 8 patients (25.81%) while a signiﬁcant decrease in
salivary function occurred in 18 (58.1%) patients and signiﬁcantly correlated with the I-131 dose.
Schirmer’s test was signiﬁcantly abnormal in those with SS. Serum Anti Ro and Anti La levels
became signiﬁcantly higher in SS patients (18.25 ± 11.61 and 25 ± 13.06 U/ml) compared to the
others (6.57 ± 1.8 and 7.35 ± 1.8 U/ml), respectively, (p 0.025 and 0.006). Fibromyalgia syndrome
was present in 12 patients (38.71%) and 6 of them developed SS.
Conclusion: Assessment and follow up of salivary and lacrimal glands function is essential in
patients receiving radioiodine therapy. Abnormal level of anti-Ro and Anti-La increase the risk
for SS that should be closely monitored and ﬁbromyalgia is a common association.
 2011 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V.
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Sjo¨gren’s syndrome (SS), the second most common autoim-
mune rheumatic disease, refers to keratoconjunctivitis sicca
and xerostomia resulting from immune lymphocytes that inﬁl-
trate the lacrimal and salivary glands. However, differential
diagnosis remains confusing due to the high prevalence of
vague symptoms of dryness, fatigue, and myalgias in the
general population. The problems of diagnosis are further
compounded by the ﬁnding of ‘‘positive’’ antinuclear antibod-
ies in a high percent of the general population [1]. Autoanti-
bodies to Ro (SSA) or La (SSB) antigens are present in the
serum of SS patients [2].
An association of SS and other autoimmune rheumatic dis-
eases as ﬁbromyalgia syndrome (FMS) has been reported [3,4].
Thyroid autoimmunity in FMS patients was similar to that in
RA and higher than normal subjects [5]. Salivary and lacrimal
gland dysfunction is relatively frequent after radioiodine ther-
apy. In most cases this is a transient side effect, but in some pa-
tients it may persist for a long period or appear late [6]. The
parotid glands have proven to be more susceptible to the devel-
opment of radiation sialadenitis than the submandibular [7,8].
Salivary scintigraphy is a useful investigation in salivary
gland diseases. In SS, pertechnetate imaging can estimate
the severity of involvement, which may not be accurately re-
ﬂected by xerostomia and other features of the sicca syn-
drome [9]. Salivary scintigraphy with semiquantitative
method is useful for accurate and reproducible assessment
of salivary gland function providing quantitative changes
after parenchymal insult whether inﬂammatory or radiation
induced [10–12]. Tc-99m sodium pertechnetate scintigraphy
is a noninvasive technique that provides functional imaging.
In addition, physiologic intervention by administration of a
sialogogue such as lemon juice provides information on the
patency of the salivary ducts and on the overall functional
integrity [13].
Iodine-131 (I-131) is an effective treatment for differenti-
ated thyroid carcinomas (DTC) after surgery. Salivary and
lacrimal gland dysfunction has been described in patients
receiving high doses of I-131 due to radiation damage.
Iodine-131 secondarily targets the salivary glands where it
is concentrated and secreted in the saliva 50–100 times to
that found in serum [14–18]. As radioiodine is concentrated
at the choroid plexus [17] and lacrimal sac [19], long-term
effects on tear secretion including xerophthalmia are consid-
ered [20]. Xerostomia, salivary swelling, pain in the parotidregion, altered taste, and dysphagia have been described
[21,22]. The symptomatology is in direct proportion to the
I-131 dosage and the passage of time. Almost two thirds
of patients who receive 100–200 mCi of I-131 will develop
salivary gland dysfunction within three months as evidenced
by scintigraphy [7,8].
Symptomatic improvement in patients with radiation-in-
duced xerostomia has been reported after pilocarpine treatment
[23]. Moreover, signiﬁcant improvement in SS symptoms was
shown [24]. Usually only increased ﬂuid intake and lemon juice
consumption is recommended for prevention of salivary gland
damage [6]. Early use of sialogogue may enhance the salivary
gland side effects of I-131 therapy and for preventing life-long
complications the timing of lemon candy sucking should be
given after 24 h [25].
The aim of the present study was to identify the occurrence
of Sjo¨gren syndrome (SS) in cancer thyroid patients after
radioactive iodine therapy (I-131), to assess the salivary and
lacrimal glands function and anti-Ro/anti-La autoantibodies
and ﬁnd a possible association to any rheumatologic diseases
including ﬁbromyalgia syndrome.
2. Patients and methods
Thirty-one patients with post-surgical differentiated thyroid
cancer (5 men, 26 women with a mean age of 40.13 ± 9.82
years (range, 25–60 years) continued the study and were re-
ferred 6–8 weeks after thyroidectomy for oral radioiodine-
131 therapy to ablate the remnant thyroid tissue or to treat
metastatic tumor. They received a mean total dose of
212.9 ± 101.63 mCi (range 110–400 mCi).
A low-iodine diet was started 10 days before 131I therapy
and thyroid hormone replacement was withdrawn 3–4 weeks
before 131I therapy. All patients were in the hypothyroid state
prior to I-131 administration with their mean serum TSH level
done 2–3 days before therapy was 28.08 ± 7.34 lIU/ml (refer-
ence normal range was 0.4–4.2 lIU/ml). All patients were
treated with L-thyroxin after therapy and none had hypothy-
roidism that might inﬂuence salivary gland function. Subjec-
tive clinical evaluation was performed to check for salivary
and lacrimal gland dysfunction before and after radioiodine
treatment. On history taking and clinical examination, there
were no symptoms or signs of sicca symptoms [26]. All the
patients were rheumatologically examined and any associated
ﬁbromyalgia syndrome (FMS) was considered according to
the ACR criteria [27].
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of classiﬁcation criteria for Sjo¨gren’s syndrome [2]. Patients
with a previous history of salivary gland disorders, diabetes,
sarcoidosis, Hepatitis C infection, pre-existing lymphoma,
Graft versus host disease, external irradiation to the head
and neck, use of anticholinergic drugs or previous I-131 ther-
apy were excluded from the study.
Salivary gland function was estimated by sequential scintig-
raphy. The patients fasted for 2 h before the study and placed
supine on the dual-head gamma camera (Siemens e-cam).
After an intravenous injection of 185 MBq (5 mCi) 99mTc-
pertechnetate, dynamic anterior acquisition was acquired in
a 128 · 128 matrix, 1 frame/30 s for 30 min set at 140 KeV
and 15% window with ·1.85 zoom. At 15th min after injec-
tion, Salivary gland secretion was stimulated with a 2 ml
freshly squeezed lemon juice (without dilution) administered
orally using a straw without moving, while imaging was con-
tinued. Patients were also instructed to minimize swallowing
during imaging. Rectangular-shaped regions of interest (ROIs)
were drawn and the time–activity curves were generated for
each region. Semiquantitative functional parameters were cal-
culated to obtain time at maximum count (Tmax) and clearance
fraction (CF). The mean values of the right and left glands
were used for data analysis.
Lacrimal gland function was measured by Schirmer’s test
performed before and after I-131 therapy during the follow-
up on the same day of doing the salivary scan using standard-
ized sterile 5 · 35 mm Schirmer’s test strips placed, without
local anesthesia, at the junction of the middle and temporal
thirds of the lower lid of the right orbit. After 5 min, the strips
were removed and evaluated by measuring the length of the
moistened area. Wetting of the paper after 5 min was consid-
ered normal when P15 mm. Dryness was considered mild,Figure 1 ROIs and actual time–activity curves of (A) parotid glands
up study 10 months after total I-131 dose of 320 mCi with lemon st
obstructive pattern. Submandibular curves show moderate and mild cmoderate and severe when the wetting of the paper was
10–14, 6–9 and 65 mm, respectively [28].
Additionally, a blood sample was obtained from each pa-
tient to investigate antinuclear antibodies (ANAs) by indirect
immunoﬂuorescence, autoantibodies anti-Ro (SS-A) and
anti-La (SS-B) by ELISA, and rheumatoid factor (RF) by
the Latex test, before and after the I-131 therapy.
Statistical Package for Social Science (SPSS) program ver-
sion 18 was used for analysis of data. Data was summarized
as mean ± SD. Mann–Whittney test was used for comparing
and analysis of two quantitative data. Spearman’s correlation
was used for detection of the relation between two variables. p-
Value was considered signiﬁcant if <0.05*.
3. Results
Initially, before radioiodine therapy the patients had no clini-
cal symptoms of dry mouth or dry eye with normal Schirmer’s
test. Salivary scintigraphy, time activity curves pattern and
semiquantitative parameters showed no abnormality. In the
follow up study (8–12 months) after last I-131dose, 18/31 pa-
tients (58.1%) gave manifestations of variable severity of sali-
vary dysfunction with xerostomia being the most common
manifestation (48.39%), xerophthalmia in 25.81%, epiphora
in 19.35%, dental problems in 48.39%, vaginal and nasal dry-
ness in 12.9 and 19.35%, respectively. Eight patients (25.81%)
fulﬁlled the criteria of classiﬁcation of primary SS. These pa-
tients showed deterioration of the salivary glands function as-
sessed by scintigraphy. Fig. 1 shows the follow up
deterioration in one of the patients who developed SS.
Abnormal Schirmer’s test was present in the 8 patients with
SS (2 severe, 2 moderate and 4 mild) with a mean of
7.63 ± 4.24 mm which was signiﬁcantly different from theand (B) submandibular glands, of a 54-years-old woman in follow
imulation at 15th min post-injection. Parotid gland curves show
learance of radioactivity in the right and left glands, respectively.
Figure 2 Correlation of the trigger points count with anti-Ro
and anti-La autoantibodies.
Table 1 Comparison of the salivary and lacrimal function parameters and autoantibodies in thyroid cancer patients before and after
iodine therapy.
Parameter (mean ± SD) (No. = 20) After 131I Before 131I Sig. p
Tmax parotid (min) 14.32 ± 3.98 12.33 ± 0.68 0.01
Tmax submandibular (min) 13.68 ± 2.45 11.82 ± 1.33 0.001
Parotid clearance (%) 58.65 ± 13.38 69.19 ± 2.89 0.000
Submandibular clearance (%) 57.19 ± 12.28 64.82 ± 4.07 0.002
Schirmer test (mm) 13.1 ± 3.87 14.74 ± 0.86 0.027
Anti/Ro (U/ml) 9.58 ± 7.8 5.55 ± 2.51 0.01
Anti/La (U/ml) 11.9 ± 10.19 7.58 ± 2.3 0.03
Bold values are signiﬁcantly different at p< 0.05.
Table 2 Comparison of the semiquantitative salivary parameters, lacrimal function and autoantibodies in thyroid cancer patients
with and without Sjo¨gren syndrome after iodine therapy.
Parameter (mean ± SD) SS (8) Without SS (23) Sig. p
Tmax parotid (min) 16.65 ± 7.25 13.52 ± 1.51 0.26
Tmax Submandibular (min) 14.93 ± 3.4 13.24 ± 1.93 0.22
Parotid clearance (%) 60.46 ± 13.2 58.03 ± 13.68 0.66
Submandibular clearance (%) 55.71 ± 14.41 57.7 ± 11.76 0.73
Schirmer test (mm) 7.63 ± 4.24 15 0.002
Anti/Ro (U/ml) 18.25 ± 11.61 6.57 ± 1.8 0.025
Anti/La (U/ml) 25 ± 13.06 7.35 ± 1.8 0.006
Bold values are signiﬁcantly different at p< 0.05.
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parameters and autoantibodies before and after iodine therapy
and in those who developed SS compared to the others are
shown in Tables 1 and 2.
Fibromyalgia syndrome (FMS) was initially present in ﬁve
(16.13%) patients and after I-131 therapy became present in 12
patients (38.71%) and 6 of them developed SS. The mean
count of tender trigger points was 5.97 ± 5.25 as almost all
the other patients had a low incomplete count. Arthralgias
were present in 12 patients and myalgias in 15 (48.39%). TheANA was initially positive in three patients (speckled pattern)
and after I-131 therapy became positive in 10 (32.26%) with
speckled pattern in eight and homogenous in two with titers
above 1/160 in all 10 patients. The Rheumatoid factor was po-
sitive in 6 patients (19.35%) before and 32.26% after I-131
therapy.
It was observed that 14 patients had received total doses
>150 mCi (mean 309.29 ± 73.11) with a signiﬁcantly altered
salivary function parameters when compared with the other
17 patients who received doses 6150 mCi (mean
133.53 ± 14.12) (p= 0.031 and 0.001 for Tmax; p= 0.009
and 0.001 for CF in the parotid and submandibular glands,
respectively). No signiﬁcant sex and age differences were found
in patients receiving above and below 150 mCi. The parotid
gland was affected more often (38.71%) than the submandib-
ular gland (25.81%). Six patients showed involvement of all
four major glands.
The Schirmer test showed a signiﬁcant negative correlation
with both anti-Ro and anti-La before (r 0.52, p 0.003) and
after (r 0.77, p 0.000 and r 0.78, p 0.000) I-131 therapy
respectively. It signiﬁcantly negatively correlated with the Tmax
of the parotid (r 0.4, p 0.027) and submandibular salivary
gland (r 0.43, p 0.015) and signiﬁcantly correlated with the
CF% in the parotid and submandibular salivary glands (r
0.36, p 0.049 and r 0.49, p0.006, respectively) before I-131 ther-
apy. The anti-Ro and anti-La did not correlate with any of the
studied parameters of the parotid or submandibular salivary
glands. The total dose of I-131 therapy signiﬁcantly negatively
correlated with the Schirmer test (r 0.36, p 0.045). It signiﬁ-
cantly correlated with Tmax parotid and submandibular (r
0.54, p 0.002 and r 0.68, p 0.000) while it was negative with
the CF% of both glands (r 0.44, p 0.013 and r 0.54, p
0.002, respectively). After I-131 therapy, the count of tender
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vel (r 0.43, p 0.017) but not with the anti-La (r 0.26, p 0.17)
(Fig. 2). Furthermore there was a tendency to a negative rela-
tion between the trigger point count and the Schirmer test (r
0.34, p 0.07).
4. Discussion
Radioiodine (I-131) secondarily targets the salivary glands
causing considerable radiation damage to these glands result-
ing in xerostomia, pain, swelling, altered taste and dysphagia.
In addition, long-term effects on the lacrimal glands causes
affection of tear secretion leading to ocular dryness and in
some cases, nasolacrimal duct obstruction [16].
In the current study 8 patients (25.81%) fulﬁlled the criteria
of classiﬁcation of primary SS. Deterioration of salivary glands
function assessed by scintigraphy indices was present in 58.1%
of patients. This is in agreement with the study of Solans et al.
who reported that abnormal objective test results were more
frequent than subjective symptoms when the salivary glands
were evaluated [6]. Salivary gland dysfunction occurred in pa-
tients receiving low and high-dose radioiodine therapy [14–
16,21,22].
In the present study, a reliance on total dose of radioiodine
was signiﬁcant for dysfunction and deterioration of the sali-
vary parameters on follow up especially in patients receiving
a total dose of >150 mCi. In accordance were the results that
found that the incidence of severe xerostomia was greater with
increasing doses of radioiodine [6] and the signiﬁcant activity-
related functional impairment after I-131 [22]. Other studies
found that severe salivary gland parenchymal destruction oc-
curred among patients who received large doses of I-131
[14,16,21,22].
In the current study the parotid gland was affected more of-
ten (38.71%) than the submandibular gland (25.81%).
Although all salivary glands are involved in the transport of
I-131 into the saliva, the parotid glands have proven to be
more susceptible to the development of radiation sialadenitis
[7,8,29]. Parotid gland secretion is usually reduced by about
40% after doses of 270 mCi of I-131 [30] and by 50–60% in
those who receive 500 mCi of I-131 [31,32], and approaches
100% in those who receive one curie of I-131or more [33]
The most common symptom of the studied patients was
xerostomia. The obstructive hypothesis afﬁrms that the radia-
tion damage causes glandular inﬂammatory inﬁltration and
concomitant swelling which may lead to an increased periduc-
tal pressure with subsequent ductal constriction [7,8,34].
In the current study, abnormal Schirmer’s test was docu-
mented in 25.81% with variable severity depending on the dose
given. There was associated xerostomia and impaired salivary
function parameters which is in accordance with the ﬁnding of
Solans et al. [6]. Schirmer’s tear test was found to be abnormal
in 40% of patients after I-131 therapy [20] as I-131 is excreted
in tears and actively accumulated in the nasolacrimal duct [35].
Obstruction of the lacrimal drainage system could occur after
high-dose radioiodine therapy [36].
Fibromyalgia syndrome (FMS) was associated in 38.71%
and half of them developed SS. Arthralgias were present in
38.71% and myalgias in 48.39% of the patients. The ANA
was initially positive in 9.68% of cases with a speckled pattern
and after I-131 therapy became positive in 32.26% (speckled ineight and homogenous in two). with titers above 1/160 in all 10
patients. The Rheumatoid factor was positive in 6 patients
(19.35%) before and 32.26% after I-131 therapy. In agreement
with these results are the ﬁndings of Solans et. al., [6] who
found that 11.4% of their patients had a positive ANA during
the ﬁrst year follow up after they were initially negative. On the
other hand, they found that those patients with initially posi-
tive ANA, became negative during the ﬁrst year followup. This
might throw light on the possible role of autoimmunity on the
glandular abnormalities and SS in these patients. They further
found RF to be positive in about 4% of cases. While another
study found that RF was positive in 25.8% of primary SS and
was closely associated with ANA and anti-SSA/SSB [37]. This
unchanged association during the study with FMS and the in-
creased positivity of ANA and RF after I-131 therapy makes
the responsibility of an underlying autoimmune disease for
the salivary glandular abnormalities and SS questionable. This
may be explained by the hypothesis that most hypothyroid
ﬁbromyalgia patients are thyroid hormone resistant [38], the
often occurrence of FMS with other rheumatic disorders and
almost 50% of FMS patients develop Sjo¨gren’s syndrome
[3]. Unlike with other rheumatic diseases, the associated
FMS may exceptionally antedate the appearance of Sjo¨gren’s
syndrome [4].
It is believed that iodine therapy might exaggerate or un-
mask the sicca symptoms in cancer thyroid patients with asso-
ciated FMS. Yet, this suggestion warrants further studies on a
larger number of patients with a longer follow up. The inci-
dence of sialadenitis after I-131 therapy is lower than before
with administration of pilocarpine if given with concurrent
stringent application of physiologic sialogogues (candy, gum,
ﬂuids), dexamethasone, and dolasetron mesylate, a serotonin
receptor antagonist [39].
It may be concluded that objective assessment of salivary
and lacrimal glands function provides a reproducible means
for follow-up after radioiodine therapy especially those receiv-
ing a total dose more than 150 mCi. Those associated with
abnormal levels of autoantibodies in association with FMS
are more prone to develop Sjo¨gren’s syndrome and should
be closely monitored after radioiodine therapy. Salivary gland
biopsy is recommended to verify the underlying pathogenesis.
Effective protection is required in patients undergoing this
treatment.Conﬂict of interest
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